Vaxcyte Doses First Participants In Phase 1/2 Clinical Study Evaluating VAX-31 For The Prevention Of Invasive Pneumococcal Disease In Adults
Portfolio Pulse from Benzinga Newsdesk
Vaxcyte, Inc. (NASDAQ:PCVX) has initiated a Phase 1/2 clinical study for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) in adults. The study will enroll approximately 1,000 adults aged 50 and older, with topline data expected in the second half of 2024. VAX-31 is designed to provide coverage for approximately 95% of IPD circulating in the U.S. adult population.
November 09, 2023 | 1:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vaxcyte has started a Phase 1/2 clinical study for its vaccine candidate VAX-31. The results of this study could have significant implications for the company's future growth and stock performance.
The initiation of the Phase 1/2 clinical study for VAX-31 represents a significant milestone for Vaxcyte. If the study results are positive, it could lead to increased investor confidence and a potential rise in the company's stock price. However, it's important to note that the results are not expected until the second half of 2024, and there are inherent risks involved in clinical trials.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100